Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Candesartan is effective in preventing cardiovascular events in patients without restenosis
after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after
drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events.
The purpose of this study is to investigate whether an angiotensin II receptor blocker,
candesartan, is effective in reducing the incidence of cardiovascular events after
drug-eluting stent implantation.